Update (November 18): After the companies concluded their Phase 3 trials and found that the vaccine is 95 percent effective in an analysis of 170 confirmed COVID-19 cases, Pfizer and BioNTech are expected to seek emergency authorization from global regulators within days. The results put the vaccine on par with competitor Moderna’s COVID-19 vaccine, which was found on Monday to be 94.5 percent effective in a preliminary analysis of 95 participants.

Preliminary data from pharmaceutical giant Pfizer and German biotechnology firm BioNTech show that their COVID-19 vaccine is more than 90 percent effective at protecting people from the infection, compared to patients who received a placebo saline shot, according to a Pfizer statement today (November 9).

“I’ve been in vaccine development for 35 years,” William Gruber, Pfizer’s senior vice president of vaccine clinical research and development, tells STAT. “I’ve seen some really good...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?